Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

161. Clopidogrel plus acetylsalicylic acid in acute coronary syndrome

Clopidogrel plus acetylsalicylic acid in acute coronary syndrome Executive Summary IQWiG Reports - Commission No. A04-01B Clopidogrel plus acetylsalicylic acid in acute coronary syndrome 1 1 Translation of the executive summary of the final report “Clopidogrel plus Acetylsalicylsäure bei akutem Koronarsyndrom” (Version 1.0; Status: 28.01.2009). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. Executive summary of final report A04-01B Version 1.0 28.01.2009 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Clopidogrel plus acetylsalicylic acid in acute coronary syndrome Contracting agency: Federal Joint Committee Commission awarded on: 15.12.2004 Internal Commission No.: A04-01B Address of publisher: Institute for Quality and Efficiency in Health Care Dillenburger Str. 27 51105 Cologne Germany Tel: +49-(0)221/35685-0 Fax

2009 Institute for Quality and Efficiency in Healthcare (IQWiG)

162. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. (PubMed)

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Mechanical reperfusion with stenting for ST-elevation myocardial infarction (STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel. Prasugrel, a potent and rapid-acting thienopyridine, is a potential alternative to clopidogrel. We aimed to assess prasugrel versus clopidogrel (...) in patients undergoing percutaneous coronary intervention (PCI) for STEMI.We undertook a double-blind, randomised controlled trial in 707 sites in 30 countries. 3534 participants presenting with STEMI were randomly assigned by interactive voice response system either prasugrel (60 mg loading, 10 mg maintenance [n=1769]) or clopidogrel (300 mg loading, 75 mg maintenance [n=1765]) and were unaware of the allocation. The primary endpoint was cardiovascular death, non-fatal myocardial infarction, or non-fatal

2009 Lancet

163. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. (PubMed)

Effect of clopidogrel added to aspirin in patients with atrial fibrillation. Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead. We investigated the hypothesis that the addition of clopidogrel to aspirin would reduce the risk of vascular events in patients with atrial fibrillation.A total of 7554 patients with atrial fibrillation who had an increased risk of stroke and for whom (...) vitamin K-antagonist therapy was unsuitable were randomly assigned to receive clopidogrel (75 mg) or placebo, once daily, in addition to aspirin. The primary outcome was the composite of stroke, myocardial infarction, non-central nervous system systemic embolism, or death from vascular causes.At a median of 3.6 years of follow-up, major vascular events had occurred in 832 patients receiving clopidogrel (6.8% per year) and in 924 patients receiving placebo (7.6% per year) (relative risk

2009 NEJM

164. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. (PubMed)

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Proton-pump inhibitors (PPIs) are often prescribed in combination with thienopyridines. Conflicting data exist as to whether PPIs diminish the efficacy of clopidogrel. We assessed the association between PPI use, measures of platelet function, and clinical outcomes for patients treated with clopidogrel or prasugrel.In the PRINCIPLE-TIMI 44 (...) intervention were randomly assigned to prasugrel (n=102) or high-dose clopidogrel (n=99). Mean inhibition of platelet aggregation was significantly lower for patients on a PPI than for those not on a PPI at 6 h after a 600 mg clopidogrel loading dose (23.2+/-19.5% vs 35.2+/-20.9%, p=0.02), whereas a more modest difference was seen with and without a PPI after a 60 mg loading dose of prasugrel (69.6+/-13.5% vs 76.7+/-12.4%, p=0.054). In the TRITON-TIMI 38 trial, 13,608 patients with an acute coronary

2009 Lancet

165. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. (Full text)

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel.In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular (...) events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation.At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P<0.001). Predefined hierarchical testing of secondary end points showed significant differences

2009 NEJM PubMed

166. CYP2C19 Genotyping to determine response to clopidogrel

CYP2C19 Genotyping to determine response to clopidogrel CYP2C19 Genotyping to determine response to clopidogrel CYP2C19 Genotyping to determine response to clopidogrel Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from . Citation CYP2C19 Genotyping to determine response to clopidogrel . Lansdale: HAYES, Inc.. 2009 Authors' objectives Dual (...) antiplatelet therapy with aspirin and clopidogrel (Plavix®; Sanofi-Aventis U.S. LLC) is recommended both in patients after acute myocardial infarction (MI) and in patients undergoing percutaneous coronary intervention (PCI) with stenting. Clopidogrel is a prodrug that requires transformation to an active metabolite in the liver by the cytochrome P450 (CYP) enzymes. The CYP genes are highly polymorphic and recent data suggest that certain alleles, particularly of the CYP2C19 gene located on chromosome 10

2009 Health Technology Assessment (HTA) Database.

167. The relative efficacy and safety of clopidogrel in women and men: a sex-specific collaborative meta-analysis (Full text)

The relative efficacy and safety of clopidogrel in women and men: a sex-specific collaborative meta-analysis The relative efficacy and safety of clopidogrel in women and men: a sex-specific collaborative meta-analysis The relative efficacy and safety of clopidogrel in women and men: a sex-specific collaborative meta-analysis Berger JS, Bhatt DL, Cannon CP, Chen Z, Jiang L, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR, Topol EJ, Berger PB CRD summary The authors concluded that clopidogrel (...) was effective in reducing the risk of cardiovascular events for both women and men. The authors’ conclusions appear to be reliable, but a risk of error and bias in the review methods should be considered. Authors' objectives To determine the efficacy and safety of clopidogrel for the prevention of cardiovascular events in women and men. Searching MEDLINE and The Cochrane Central Register of Controlled Trials (CENTRAL) were searched for studies published between 1999 and May 2007. The search terms were

2009 DARE. PubMed

168. Clopidogrel for the treatment of adult patients following acute coronary syndrome

Clopidogrel for the treatment of adult patients following acute coronary syndrome The Therapeutics Initiative | Evidence-Based, Practical Prescription Drug Therapy Information Independent Healthcare Evidence What’s New April 2, 2019 THE VALUE OF INDEPENDENT DRUG ASSESSMENT Issue: BCMJ, vol. 61 , No. 3 , April 2019 , Pages 125-127 Premise By: James M. Wright, MD, PhD, FRCPC Ken Bassett, MD, PhD Thomas L. Perry Jr., MD Aaron M. Tejani, PharmD Type 2 diabetes in British … February 28, 2019 "3D

2009 Therapeutics Letter

169. Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI

Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI Article Text Aetiology

2009 Evidence-Based Medicine (Requires free registration)

170. Clopidogrel versus other antiplatelet agents in the secondary prevention of vascular events in adults with cerebrovascular disease: clinical and cost-effectiveness analyses

Clopidogrel versus other antiplatelet agents in the secondary prevention of vascular events in adults with cerebrovascular disease: clinical and cost-effectiveness analyses Clopidogrel versus other antiplatelet agents in the secondary prevention of vascular events in adults with cerebrovascular disease: clinical and cost-effectiveness analyses Clopidogrel versus other antiplatelet agents in the secondary prevention of vascular events in adults with cerebrovascular disease: clinical and cost (...) -effectiveness analyses Banerjee S, Brown A, Hutton B, McGahan L, Asakawa K, Clark M, Severn M, Cox JL, Sharma M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Banerjee S, Brown A, Hutton B, McGahan L, Asakawa K, Clark M, Severn M, Cox JL, Sharma M. Clopidogrel versus other antiplatelet agents in the secondary prevention of vascular events in adults

2009 Health Technology Assessment (HTA) Database.

171. Aspirin plus extended-release dipyridamole and clopidogrel were similarly effective for preventing recurrent stroke

Aspirin plus extended-release dipyridamole and clopidogrel were similarly effective for preventing recurrent stroke Aspirin plus extended-release dipyridamole and clopidogrel were similarly effective for preventing recurrent stroke | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin plus extended-release dipyridamole and clopidogrel were similarly effective for preventing recurrent stroke Article Text Therapeutics Aspirin plus extended

2009 Evidence-Based Medicine (Requires free registration)

172. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis

The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

173. Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials

Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

174. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis

The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 Health Technology Assessment (HTA) Database.

175. Clopidogrel BGR (previously Zylagren) - clopidogrel

Clopidogrel BGR (previously Zylagren) - clopidogrel European Medicines Agency Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 45 E-mail: mail@emea.europa.eu http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged. Doc. Ref.:EMEA/507032/2009 CHMP ASSESSMENT REPORT FOR ZYLAGREN International Nonproprietary Name: clopidogrel Procedure (...) of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Zylagren on 25 June 2009. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 23 June 2009. 4/13 © EMEA 2009 2. SCIENTIFIC DISCUSSION .1 Introduction ylagren 75mg film-coated tablets are generic medicinal products containing clopidogrel as lopidogrel is a non-competitive inhibitor of adenosine

2009 European Medicines Agency - EPARs

176. Clopidogrel TAD

Clopidogrel TAD European Medicines Agency 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 45 E-mail: mail@emea.europa.eu http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged. Doc. Ref.:EMEA/506902/2009 CHMP ASSESSMENT REPORT FOR Clopidogrel TAD International Nonproprietary Name: clopidogrel Procedure No. EMEA/H/C/001136 Assessment Report as adopted by the CHMP with all (...) of the dossier Tad Pharma GmbH submitted on 20 February 2009 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for Clopidogrel Tad , in accordance with the centralised procedure falling within the scope of the Annex to Regulation (EC) 726/2004 under Article 3 (3) – ‘Generic of a Centrally authorised product’. The legal basis for this application refers to Article 10(1) of Directive 2001/83/EC. The chosen reference product is: ¦ Medicinal product which is or has been

2009 European Medicines Agency - EPARs

177. Clopidogrel ratiopharm GmbH

Clopidogrel ratiopharm GmbH European Medicines Agency Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 45 E-mail: mail@emea.europa.eu http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged. Doc. Ref:EMEA/533408/2009 ASSESSMENT REPORT FOR Clopidogrel ratiopharm GmbH International Nonproprietary Name: clopidogrel Procedure No. EMEA/H/C/1165 (...) INFORMATION ON THE PROCEDURE 1.1 Submission of the dossier The applicant Acino Pharma GmbH submitted on 17 April 2009 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for Clopidogrel ratiopharm GmbH, in accordance with the centralised procedure falling within the scope of the Annex to Regulation (EC) 726/2004 under Article 3 (3) – ‘Generic of a Centrally authorised product’. The legal basis for this application refers to Article 10(1). The chosen reference product

2009 European Medicines Agency - EPARs

178. Clopidogrel Acino

Clopidogrel Acino European Medicines Agency Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 45 E-mail: mail@emea.europa.eu http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged. Doc. Ref:EMEA/533424/2009 ASSESSMENT REPORT FOR Clopidogrel Acino International Nonproprietary Name: clopidogrel Procedure No. EMEA/H/C/1166 Assessment Report (...) product no longer authorised3/13 1. BACKGROUND INFORMATION ON THE PROCEDURE 1.1 Submission of the dossier The applicant Acino Pharma GmbH submitted on 17 April 2009 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for Clopidogrel Acino, in accordance with the centralised procedure falling within the scope of the Annex to Regulation (EC) 726/2004 under Article 3 (3) – ‘Generic of a Centrally authorised product’. The legal basis for this application refers to Article 10

2009 European Medicines Agency - EPARs

179. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. (PubMed)

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Clopidogrel and low-dose aspirin have become the mainstay oral antiplatelet regimen to prevent recurrent ischaemic events after acute coronary syndromes or stent placement. The frequent genetic functional variant 681 G>A (*2) of cytochrome P450 2C19 (CYP2C19) is an important contributor to the wide variability between individuals of the antiplatelet effect of clopidogrel. We (...) assessed whether the CYP2C19*2 polymorphism affected long-term prognosis of patients who were chronically treated with clopidogrel.Between April 1, 1996, and April 1, 2008, 259 young patients (aged <45 years) who survived a first myocardial infarction and were exposed to clopidogrel treatment for at least a month, were enrolled in a multicentre registry and underwent CYP2C19*2 determination. The primary endpoint was a composite of death, myocardial infarction, and urgent coronary revascularisation

2008 Lancet

180. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. (PubMed)

Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. Pharmacogenetic determinants of the response of patients to clopidogrel contribute to variability in the biologic antiplatelet activity of the drug. The effect of these determinants on clinical outcomes after an acute myocardial infarction is unknown.We consecutively enrolled 2208 patients presenting with an acute myocardial infarction in a nationwide French registry and receiving clopidogrel therapy. We then assessed (...) the relation of allelic variants of genes modulating clopidogrel absorption (ABCB1), metabolic activation (CYP3A5 and CYP2C19), and biologic activity (P2RY12 and ITGB3) to the risk of death from any cause, nonfatal stroke, or myocardial infarction during 1 year of follow-up.Death occurred in 225 patients, and nonfatal myocardial infarction or stroke in 94 patients, during the follow-up period. None of the selected single-nucleotide polymorphisms (SNPs) in CYP3A5, P2RY12, or ITGB3 were associated

2008 NEJM